The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Mel'nichenko A.B.

I.M. Sechenov First Moscow State Medical University, Moscow

Kochergin N.G.

I.M. Sechenov Moscow Medical Academy

Belousova T.A.

I.M. Sechenov First Moscow State Medical University, Moscow

Psoriatic arthritis: clinical features, diagnostics, and treatment

Authors:

Mel'nichenko A.B., Kochergin N.G., Belousova T.A.

More about the authors

Read: 49977 times


To cite this article:

Mel'nichenko AB, Kochergin NG, Belousova TA. Psoriatic arthritis: clinical features, diagnostics, and treatment. Russian Journal of Clinical Dermatology and Venereology. 2010;8(5):17‑24. (In Russ.)

Recommended articles:
Search of diagnostic and prognostic biomarkers of immu­noinflammatory dermatoses by means of flow cyto­metry. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):170-177
Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xero­sis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):178-184
Historical aspe­cts and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):284-292
Key specific tools for asse­ssment of life quality of patients with psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):319-325
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
New approach to clinical evaluation of nail lesions in psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):453-460
Unde­restimated itching symptom in psoriasis: diagnostic limi­tations and correction paths. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):675-682

References:

  1. Myers W.A., Gottlieb A.B., Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006; 24: 5: 438-447.
  2. Landells I., MacCallum C., Khraishi M. The Role of the Dermatologist in Identification and Treatment of the Early Stages of Psoriatic Arthritis. Skin Ther Let 2008; 13: 4: 4-7.
  3. Gottlieb A., Neil J. Korman, Kenneth B. Gordon et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2008; 58: 851-864.
  4. Lebwohl M. Psoriasis. Lancet 2003; 361: 9364: 1197-1204.
  5. Myers W., Opeola M., Gottlieb A.B. Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2004; 6: 4: 306-313.
  6. Kochergin N.G., Smirnova L.M., Potekaev N.N., Bilalova U.V. Psoriaz: komorbidnosti i komedikatsii. Vrach 2009; 5: 15-20.
  7. Stern R.S. The epidemiology of joint complaints in patients with psoriasis. J Rheumatol 1985; 12: 2: 315-320.
  8. Badokin V.V. Sovremennaya terapiya psoriaticheskogo artrita. Consilium Medicum 2005; 3: 35-41.
  9. Quershi A.A., Husni M.E., Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg 2005; 24: 1: 46-51.
  10. Weinstein G.D., Gottlieb A.B. ed. Therapy of Moderate to Severe Psoriasis, 2nd ed. New York: Marcel Dekker 2003.
  11. Ferrandiz C., Pujol R.M., Garcia-Patos V. et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002; 46: 6: 867-873.
  12. Henseler T., Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 3: 450-456.
  13. Cohen M.R., Reda D.J., Clegg D.O. Baseline relationships between psoriasis and psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 1999; 26: 8: 1752-1756.
  14. Gladman D.D., Anhorn K.A., Schachter R.K. et al. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13: 3: 586-592.
  15. Williamson L., Dalbeth N., Dockerty J.L. et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43: 6: 790-794.
  16. Alenius G.M. Psoriatic arthritis - new insights give new options for treatment. Curr Med Chem 2007; 14: 3: 359-366.
  17. Yates V.M., Watkinson G., Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982; 106: 3: 323-330.
  18. Hellgren L. Association between rheumatoid arthritis and psoriasis in total populations. Acta Rheum Scand 1969; 15: 316-326.
  19. Brockbank J., Gladman D. Diagnosis and management of psoriatic arthritis. Drugs 2002; 62: 17: 2447-2457.
  20. Taylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 8: 2665-2673.
  21. Ory P.A., Gladman D.D., Mease P.J. Psoriatic arthritis and imaging. Ann Rheum Dis 2005; 64 (Suppl): 55-57.
  22. Nash P., Clegg D.O. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005; 64 (Suppl): 74-77.
  23. Black R.L., O'Brien W.M., Vanscott E.J. et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964; 189: 743-747.
  24. Willkens R.F., Williams H.J., Ward J.R. et al. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376-381.
  25. Clegg D.O., Reda D.J., Mejias E. et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A Department of Veterans Affairs cooperative study. Arthritis Rheum 1996; 39: 2013-2020.
  26. Kaltwasser J.P., Nash P., Gladman D. et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50: 1939-1950.
  27. Kurdina M.I. Antitsitokinovaya terapiya - novoe napravlenie v lechenii psoriaza. Vestn dermatol 2005; 1: 3-8.
  28. Nasonov E.L. Primenenie infliksimaba pri revmaticheskikh zabolevaniyakh. M 2005; 56.
  29. Smirnova L.M., Kochergin N.G. Infliksimab pri psoriaze: evropeiskii vzglyad. Rus med zhurn 2006; 5: 362-369.
  30. Kochergin N.G. Psoriaz: poslednie novosti. Consilium Medicum. Dermatologiya 2007; 2: 14-17.
  31. Soriano E.R., McHugh N.J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumanol 2006; 33: 7: 1422-1430.
  32. Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-1157.
  33. Mease P.J., Gladman D.D., Ritchlin C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-3289.
  34. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272.
  35. Queiro-Silva R., Torre-Alonso J.C., Tinture-Eguren T., Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003; 62: 68-70.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.